Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the breast cancer association consortium studies

Journal of the National Cancer Institute

Volumn 103, Issue 3, 2011, Pages 250-263

  Yang, Xiaohong R ^a   Chang Claude, Jenny ^b   Goode, Ellen L ^c   Couch, Fergus J ^d   Nevanlinna, Heli ^e   Milne, Roger L ^d   Gaudet, Mia ^d   Schmidt, Marjanka K ^d   Broeks, Annegien ^d   Cox, Angela ^f   Fasching, Peter A ^g   Hein, Rebecca ^h   Spurdle, Amanda B ⁱ   Blows, Fiona ^j   Driver, Kristy ^k   Flesch Janys, Dieter ^l   Heinz, Judith ^m   Sinn, Peter ⁿ   Vrieling, Alina ^o   Heikkinen, Tuomas ^p   Aittomäki, Kristiina ^q   Heikkilä, Päivi ^r   Blomqvist, Carl ^s   Lissowska, Jolanta ^t   Peplonska, Beata ^u   Chanock, Stephen ^v   Figueroa, Jonine ^w   Brinton, Louise ^x   Hall, Per ^y   Czene, Kamila ^z   Humphreys, Keith ^aa   Darabi, Hatef ^ab   Liu, Jianjun ^ac   Van 'T Veer, Laura J ^ad   Van Leeuwen, Flora E ^ae   Andrulis, Irene L ^af   Glendon, Gord ^ag   Knight, Julia A ^ah   Mulligan, Anna Marie ^d   O'Malley, Frances P ^ai   Weerasooriya, Nayana ^aj   John, Esther M ^ak   Beckmann, Matthias W ^al   Hartmann, Arndt ^am   Weihbrecht, Sebastian B ^an   Wachter, David L ^c   Jud, Sebastian M ^ao   Loehberg, Christian R ^ap   Baglietto, Laura ^aq   English, Dallas R ^ar   Giles, Graham G ^as   McLean, Catriona A ^at   Severi, Gianluca ^au   Lambrechts, Diether ^av   Vandorpe, Thijs ^aw   Weltens, Caroline ^ax   Paridaens, Robert ^d   Smeets, Ann ^ay   Neven, Patrick ^az   Wildiers, Hans ^ba   Wang, Xianshu ^bb   Olson, Janet E ^d   Cafourek, Victoria ^u   Fredericksen, Zachary ^bc   Kosel, Matthew ^bd   Vachon, Celine ^be   Cramp, Helen E ^bf   Connley, Daniel ^bg   Cross, Simon S ^bh   Balasubramanian, Sabapathy P ^bg   Reed, Malcolm W R ^bi   Dörk, Thilo ^bj   Bremer, Michael ^bk   Meyer, Andreas ^bl   Karstens, Johann H ^bm   Ay, Aysun ^bn   Park Simon, Tjoung Won ^bo   Hillemanns, Peter ^bp   Arias Pérez, Jose Ignacio ^d   Rodríguez, Primitiva Menéndez ^d   Zamora, Pilar ^bq   Benítez, Javier ^bd   Ko, Yon Dschun ^ae   Fischer, Hans Peter ^b   Hamann, Ute ^e   Pesch, Beate ^d   Brüning, Thomas ^d   Justenhoven, Christina ^d   Brauch, Hiltrud ^av   Eccles, Diana M ^b   Tapper, William J ^e   Gerty, Sue M ^ad   Sawyer, Elinor J ^c   Tomlinson, Ian P ^an   Jones, Angela ^u   Kerin, Michael ^au   Miller, Nicola ^c   McInerney, Niall ^bf   Anton Culver, Hoda ^bp   Ziogas, Argyrios ^d   Shen, Chen Yang ^ak   Hsiung, Chia Ni ^ax   Wu, Pei Ei ^ax   Yang, Show Lin ^ad   Yu, Jyh Cherng ^t   Chen, Shou Tung ^t   Hsu, Giu Cheng ^an   Haiman, Christopher A ^an   Henderson, Brian E ^an   Le Marchand, Loic ^an   Kolonel, Laurence N ^bp   Lindblom, Annika ^bf   Margolin, Sara ^av   Jakubowska, Anna ^e   Lubiński, Jan ^c   Huzarski, Tomasz ^c   Byrski, Tomasz ^d   Górski, Bohdan ^d   Gronwald, Jacek ^d   Hooning, Maartje J ^c   Hollestelle, Antoinette ^bf   Van Den Ouweland, Ans M W ^an   Jager, Agnes ^ax   Kriege, Mieke ^e   Tilanus Linthorst, Madeleine M A ^d   Collée, Margriet ^ae   Wang Gohrke, Shan ^aw   Pylkäs, Katri ^d   Jukkola Vuorinen, Arja ^d   Mononen, Kari ^d   Grip, Mervi ^d   Hirvikoski, Pasi ^d   Winqvist, Robert ^d   Mannermaa, Arto ^d   Kosma, Veli Matti ^c   Kauppinen, Jaana ^d   Kataja, Vesa ^d   Auvinen, Päivi ^d   Soini, Ylermi ^d   Sironen, Reijo ^d   Bojesen, Stig E ^bp   Dynnes Ørsted, David ^d   Kaur Knudsen, Diljit ^d   Flyger, Henrik ^ad   Nordestgaard, Børge G ^d   Holland, Helene ^b   Chenevix Trench, Georgia ^d   Manoukian, Siranoush ^e   Barile, Monica ^e   Radice, Paolo ^bk   Hankinson, Susan E ^d   Hunter, David J ^bf   Tamimi, Rulla ^bn   Sangrajrang, Suleeporn ^d   Brennan, Paul ^d   McKay, James ^d   Odefrey, Fabrice ^ax   Gaborieau, Valerie ^c   Devilee, Peter ^ax   Huijts, P E A ^be   Tollenaar, Raem ^d   Seynaeve, C ^d   Dite, Gillian S ^b   Apicella, Carmel ^d   Hopper, John L ^b   Hammet, Fleur ^b   Tsimiklis, Helen ^ad   Smith, Letitia D ^aw   Southey, Melissa C ^an   Humphreys, Manjeet K ^bd   Easton, Douglas ^be   Pharoah, Paul ^s   Sherman, Mark E ^h   Garcia Closas, Montserrat ^f   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Department of Health Sciences Research ^*  (United States)

^e MAYO CLINIC   (United States)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g Genetic and Molecular Epidemiology Group   (United States)

^h Centro Nacional de Investigaciones Oncológicas   (Spain)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j NETHERLANDS CANCER INSTITUTE   (Netherlands)

^k Department of Oncology   (United States)

^l UNIVERSITY OF SHEFFIELD   (United Kingdom)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^o ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^p UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^q UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^r UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^s INSTITUTE OF ONCOLOGY   (Poland)

^t NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^u KAROLINSKA INSTITUTE   (Sweden)

^v GENOME INSTITUTE OF SINGAPORE   (Singapore)

^w CANCER CARE ONTARIO   (Canada)

^x UNIVERSITY OF TORONTO   (Canada)

^y UNIVERSITY OF TORONTO   (Canada)

^z ST MICHAEL'S HOSPITAL   (Canada)

^aa MOUNT SINAI HOSPITAL   (Canada)

^ab NORTHERN CALIFORNIA CANCER CENTER   (United States)

^ac STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ad CANCER EPIDEMIOLOGY CENTRE   (Australia)

^ae UNIVERSITY OF MELBOURNE   (Australia)

^af ALFRED HOSPITAL   (Australia)

^ag UNIVERSITY OF LEUVEN   (Belgium)

^ah UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ai HANNOVER MEDICAL SCHOOL   (Germany)

^aj HOSPITAL MONTE NARANCO   (Spain)

^ak HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^al CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^am Johanniter Krankenhaus   (Germany)

^an UNIVERSITY OF BONN   (Germany)

^ao INSTITUT DER RUHR UNIVERSITÄT BOCHUM IPA   (Germany)

^ap DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^aq UNIVERSITY OF TÜBINGEN   (Germany)

^ar UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^as GUY S HOSPITAL   (United Kingdom)

^at UNIVERSITY OF OXFORD   (United Kingdom)

^au UNIVERSITY HOSPITAL GALWAY   (Ireland)

^av UNIVERSITY OF CALIFORNIA   (United States)

^aw INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^ax CHINA MEDICAL UNIVERSITY   (Taiwan)

^ay TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^az CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^ba UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^bb UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^bc POMERANIAN MEDICAL UNIVERSITY   (Poland)

^bd ERASMUS MEDICAL CENTER   (Netherlands)

^be UNIVERSITY OF ULM   (Germany)

^bf UNIVERSITY OF OULU   (Finland)

^bg KUOPIO UNIVERSITY HOSPITAL   (Finland)

^bh VAASA CENTRAL HOSPITAL   (Finland)

^bi PETER MACCALLUM CANCER CENTRE   (Australia)

^bj GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^bk Unit of Medical Genetics   (Italy)

^bl EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^bm BRIGHAM AND WOMEN S HOSPITAL   (United States)

^bn HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^bo NATIONAL CANCER INSTITUTE   (Thailand)

^bp INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^bq LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENARCHE; NULLIPARA; OBESITY; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE;

AGE FACTORS; BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; KERATIN-5; LOGISTIC MODELS; MENARCHE; OBESITY; ODDS RATIO; PARITY; PARTURITION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551694006     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq526     Document Type: Article

References (68)

1. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-5374. (Pubitemid 39100473)
2. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368-1376. (Pubitemid 351413917)
3. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.
4. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1558-1568. (Pubitemid 39331875)
5. Anderson WF, Chu KC, Chang S, et al. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13(7):1128-1135. (Pubitemid 38917901)
6. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat. 2005;90(2):127-137. (Pubitemid 40568896)
7. Ma H, Bernstein L, Pike MC, et al. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006;8(4):R43.
8. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res. 2008;14(24):8000-8009.
9. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123-139. (Pubitemid 351538762)
10. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26(14):2126-2132. (Pubitemid 46514749)
11. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264-271. (Pubitemid 43117611)
12. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22-34. (Pubitemid 43972917)
13. Habel LA, Stanford JL. Hormone receptors and breast cancer. Epidemiol Rev. 1993;15(1):209-219. (Pubitemid 23269084)
14. Dite GS, Jenkins MA, Southey MC, et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst. 2003;95(6):448-457. (Pubitemid 36432419)
15. Schmidt MK, Tollenaar RA, De Kemp SR, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25(1):64-69. (Pubitemid 350003052)
16. Fasching PA, Loehberg CR, Strissel PL, et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat. 2008;112(1):89-98.
17. Colleran G, McInerney N, Rowan A, et al. The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer. Breast Cancer Res Treat. 2010;119(2):437-442.
18. Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, et al. No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype. Br J Cancer. 2005;93(1):167-171. (Pubitemid 41076265)
19. Milne RL, Ribas G, Gonzalez-Neira A, et al. ERCC4 associated with breast cancer risk: a two-stage case-control study using high-throughput genotyping. Cancer Res. 2006;66(19):9420-9427. (Pubitemid 44623638)
20. Pesch B, Ko Y, Brauch H, et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol. 2005;20(8):699-711. (Pubitemid 41266867)
21. Chang-Claude J, Eby N, Kiechle M, et al. Breastfeeding and breast cancer risk by age 50 among women in Germany. Cancer Causes Control. 2000;11(8):687-695.
22. Dork T, Bendix R, Bremer M, et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res. 2001;61(20):7608-7615. (Pubitemid 32995055)
23. Syrjakoski K, Vahteristo P, Eerola H, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2000;92(18):1529-1531.
24. Lindblom A, Rotstein S, Larsson C, et al. Hereditary breast cancer in Sweden: a predominance of maternally inherited cases. Breast Cancer Res Treat. 1992;24(2):159-165. (Pubitemid 23063898)
25. Hartikainen JM, Tuhkanen H, Kataja V, et al. An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found. Cancer Epidemiol Biomarkers Prev. 2005;14(1):75-80. (Pubitemid 40165286)
26. Beesley J, Jordan SJ, Spurdle AB, et al. Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2557-2565. (Pubitemid 351196309)
27. De Maeyer L, Van Limbergen E, De Nys K, et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol. 2008;26(2):335-336. author reply 336-8.
28. Flesch-Janys D, Slanger T, Mutschelknauss E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer. 2008;123(4):933-941. (Pubitemid 352032424)
29. Catucci I, Verderio P, Pizzamiglio S, et al. SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis. 2009;30(3):544-545; author reply 546.
30. Olson JE, Ma CX, Pelleymounter LL, et al. A comprehensive examination of CYP19 variation and breast density. Cancer Epidemiol Biomarkers Prev. 2007;16(3):623-265.
31. Giles GG, English DR. The Melbourne Collaborative Cohort Study. IARC Sci Publ. 2002;156:69-70.
32. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol. 2000;151(4):346-357. (Pubitemid 30463612)
33. John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004;6(4):R375-R389.
34. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90(17):1292-1299. (Pubitemid 28433474)
35. Erkko H, Xia B, Nikkila J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446(7133):316-319. (Pubitemid 46426155)
36. De Bock GH, Schutte M, Krol-Warmerdam EM, et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet. 2004;41(10):731-735. (Pubitemid 39389288)
37. Garcia-Closas M, Brinton LA, Lissowska J, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer. 2006;95(1):123-129. (Pubitemid 43980566)
38. Eccles D, Gerty S, Simmonds P, et al. Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer. 2007;7:160.
39. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087- 1093. (Pubitemid 47014426)
40. Wedren S, Lovmar L, Humphreys K, et al. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res. 2004;6(4):R437-R449.
41. MacPherson G, Healey CS, Teare MD, et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst. 2004;96(24):1866-1869. (Pubitemid 40081324)
42. Lesueur F, Pharoah PD, Laing S, et al. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum Mol Genet. 2005;14(16):2349-2356. (Pubitemid 41417997)
43. Sangrajrang S, Schmezer P, Burkholder I, et al. Polymorphisms in three base excision repair genes and breast cancer risk in Thai women. Breast Cancer Res Treat. 2008;111(2):279-288.
44. Ding SL, Yu JC, Chen ST, et al. Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility. Carcinogenesis. 2009;30(1):43-49.
45. Anton-Culver H, Cohen PF, Gildea ME, et al. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer. 2000;36(10):1200-1208. (Pubitemid 30407006)
46. Jakubowska A, Jaworska K, Cybulski C, et al. Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? Eur J Cancer. 2009;45(5):837-842.
47. Bolton KL, Garcia-Closas M, Pfeiffer RM, et al. Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2010;19(4):992-999.
48. Sherman ME, Rimm DL, Yang XR, et al. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer. 2007;121(5):1079-1085. (Pubitemid 47101646)
49. Collins LC, Marotti JD, Baer HJ, et al. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst. 2008;100(3):218-221. (Pubitemid 351480544)
50. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
51. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. (Pubitemid 37088507)
52. Anderson WF, Pfeiffer RM, Dores GM, et al. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1899-1905. (Pubitemid 44664266)
53. Setiawan VW, Monroe KR, Wilkens LR, et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009;169(10):1251-1259.
54. Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol. 2010;27(3):926-931.
55. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97(17):1254-1261. (Pubitemid 41535366)
56. Kim HJ, Cui X, Hilsenbeck SG, et al. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006;12(3, pt 2):1013s-1018s. (Pubitemid 43259837)
57. Madigan MP, Troisi R, Potischman N, et al. Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). Cancer Causes Control. 1998;9(2):199-207. (Pubitemid 28160975)
58. Ursin G, Longnecker MP, Haile RW, et al. A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology. 1995;6(2):137-141.
59. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer. 2004;111(5):762-771. (Pubitemid 39062901)
60. Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev. 2007;28(7):763-777. (Pubitemid 350294295)
61. Peacock SL, White E, Daling JR, et al. Relation between obesity and breast cancer in young women. Am J Epidemiol. 1999;149(4):339-346. (Pubitemid 29302106)
62. Tehard B, Clavel-Chapelon F. Several anthropometric measurements and breast cancer risk: results of the E3N cohort study. Int J Obes (Lond). 2006;30(1):156-163. (Pubitemid 41790792)
63. Maiti B, Kundranda MN, Spiro TP, et al. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat. 2010;121(2):479-483.
64. Pichard C, Plu-Bureau G, Neves ECM, et al. Insulin resistance, obesity and breast cancer risk. Maturitas. 2008;60(1):19-30.
65. Suzuki R, Orsini N, Saji S, et al. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status - a meta-analysis. Int J Cancer. 2009;124(3):698-712.
66. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology. 1978;103(5):1742-1751. (Pubitemid 9051866)
67. Brinton LA, Richesson D, Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3150-3160.
68. Lahmann PH, Cust AE, Friedenreich CM, et al. Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;126(10):2404-2415.